NCT05070546: A reported trial by Janssen Vaccines & Prevention B.V.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05070546 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 29, 2021 |
| Completion date | Aug. 12, 2022 |
| Required reporting date | Aug. 12, 2023, midnight |
| Actual reporting date | Aug. 11, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |